STOCK TITAN
  1. Home
  2. News
  3. BSGM

BioSig Technologies, Inc. - BSGM STOCK NEWS

Welcome to our dedicated page for BioSig Technologies news (Ticker: BSGM), a resource for investors and traders seeking the latest updates and insights on BioSig Technologies stock.

BioSig Technologies, Inc. (Nasdaq: BSGM) is a Minneapolis-based medical technology company focused on the development and commercialization of advanced digital signal processing technology. The company aims to revolutionize the $3 billion electrophysiology (EP) market with its flagship product, the PURE EP™ Platform. This FDA-cleared, non-invasive class II device combines innovative hardware and software to provide unparalleled clarity and precision in visualizing intracardiac signals. The technology facilitates highly targeted cardiac ablation procedures, improving procedural efficiency and patient outcomes.

BioSig's commitment to addressing healthcare's critical priorities—saving time, reducing costs, and saving lives—is reflected in its collaborative efforts with leading medical centers, including the Cleveland Clinic, Mayo Clinic, and Texas Cardiac Arrhythmia Institute. The PURE EP™ Platform's Near-Field Tracking (NFT) algorithm, introduced in Q4 2023, has already demonstrated a significant reduction in ablation time by approximately 66%, highlighting its potential to enhance clinical procedures.

Despite recent challenges, including workforce reductions and strategic shifts, BioSig remains focused on expanding its product's adoption and exploring new market opportunities. The company recently appointed Bridge Associates International Pharmaceutical Consulting (BAIPC) to advise on business model strategies and continues to work on potential commercialization opportunities within the AI space.

Under the leadership of a new CEO and a reconstituted Board of Directors, BioSig is committed to restoring and creating lasting shareholder value. The company has also addressed compliance issues with the Nasdaq Hearings Panel, further solidifying its position in the marketplace.

For more information and the latest updates, visit the SEC's website.

News

BioSig Adds Five New Patent Awards to 100+ Total Patent Portfolio Covering Digital Signal Processing Technology and AI

Rhea-AI Summary
BioSig Technologies has been awarded five new utility patents by the U.S. Patent and Trademark Office for its PURE EP digital signal processing technology. The patents cover various aspects of signal visualization and processing in cardiac signals. BioSig now has a total of 35 issued and allowed utility patents, 30 issued design patents, and 23 pending utility patent applications for the PURE EP platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.9%
Tags
AI
-
News

BioSig AI Sciences Achieves Infrastructure and Technology progress in Development of Generative AI Platform for Hospitals

Rhea-AI Summary
BioSig Technologies provides update on AI medical device platform development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.7%
Tags
AI
-
News

BioSig Introduces New Subscription Model for PURE EP™ Platform, Offering Quicker Access to Latest Features, Customizations

Rhea-AI Summary
Cleveland Clinic signs on as first subscriber to BioSig's PURE EP Platform
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
none
News

BioSig's PURE EP™ Platform Debuts New Automated Features in First Patient Cases

Rhea-AI Summary
BioSig Technologies releases new software features for the PURE EP™ Platform, enhancing capabilities for electrophysiologists to visualize heart patterns. The features include Near-Field Tracking (NFT) and Automatic Tachycardia Characterization (ATC). The software upgrade builds on existing features like PURE ZONE™ and High Frequency Algorithm (HFA). Research shows a 66% reduction in procedure time with PURE EP™, potentially leading to cost savings of $418.10 per procedure and over $30 million annually for healthcare. The update also allows for additional reimbursement options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.76%
Tags
none
-
News

BioSig AI Sciences Receives $2.2 Million in Seed Funding to Advance Development of Artificial Intelligence Applications

Rhea-AI Summary
BioSig Technologies, Inc. has completed a seed funding round, raising $2.2 million for its subsidiary, BioSig AI Sciences, Inc. The subsidiary aims to advance the research and development of an artificial intelligence medical device platform. The collaboration between BioSig and Reified Labs has resulted in multiple patent applications and a research publication on AI-enhanced electrocardiogram lead placement mapping. The market for artificial intelligence in healthcare is projected to reach $272.9 billion by 2030, with a CAGR of 51.9%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.98%
Tags
AI
-
News

BioSig AI Sciences Selected for NVIDIA Inception Partnership Program to Support R&D Collaboration on AI Medical Device Platform for Hospitals

Rhea-AI Summary
BioSig Technologies' subsidiary, BioSig AI Sciences, has been selected to join NVIDIA Inception, a program that supports companies revolutionizing industries with AI advancements. This partnership will provide engineering guidance, technical training, and exposure to the NVIDIA investment community. BioSig plans to leverage NVIDIA's resources to advance its AI medical device platform and identify transformative applications in healthcare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.92%
Tags
partnership AI
News

BioSig Joins Webull Corporate Connect

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
none
-
News

BioSig Advances Collaboration on Machine Learning and Artificial Intelligence Solutions for Healthcare

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.03%
Tags
none
-
News

New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
none
News

New Data at Heart Rhythm 2023 Suggests that Unipolar Signals May be Used for a More Precise, Accurate Approach to Treating Arrhythmias

Rhea-AI Summary
Researchers from Cleveland Clinic presented data from three abstracts at Heart Rhythm 2023, highlighting the potential of an optimized radiofrequency ablation technique for pulmonary vein isolation (PVI) using BioSig Technologies' PURE EP™ platform. The studies showed that using unipolar signals for guidance improved lesion precision, reduced procedure time, and maintained accuracy compared to the current standard of using the Ablation Index™. The findings have implications for improving radiofrequency ablation techniques for atrial fibrillation treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
none

FAQ

What is the current stock price of BioSig Technologies (BSGM)?

The current stock price of BioSig Technologies (BSGM) is $1.49 as of December 23, 2024.

What is the market cap of BioSig Technologies (BSGM)?

The market cap of BioSig Technologies (BSGM) is approximately 22.9M.

What does BioSig Technologies, Inc. do?

BioSig Technologies, Inc. is a medical technology company specializing in advanced digital signal processing technology for the electrophysiology market. Their flagship product, PURE EP™ Platform, enhances intracardiac signal visualization and facilitates targeted cardiac ablation procedures.

What is the PURE EP™ Platform?

The PURE EP™ Platform is an FDA-cleared, non-invasive class II medical device that combines hardware and software to provide real-time, high-clarity visualization of intracardiac signals, aiding in efficient and precise cardiac ablation procedures.

Who are BioSig's collaborators?

BioSig collaborates with leading healthcare institutions such as the Cleveland Clinic, Mayo Clinic, and Texas Cardiac Arrhythmia Institute to improve the efficacy and efficiency of electrophysiology procedures.

What recent achievements has BioSig made?

Recent achievements include the introduction of the Near-Field Tracking (NFT) algorithm, which has significantly reduced ablation time by 66%, and the appointment of Bridge Associates International Pharmaceutical Consulting to advise on business strategies.

How is BioSig addressing its financial and operational challenges?

BioSig has implemented workforce reductions and strategic shifts to reduce cash burn and is actively seeking partnerships for sales distribution and clinical support. The company is also exploring AI-driven opportunities for its product portfolio.

What are BioSig's future plans?

BioSig plans to expand the clinical adoption of its PURE EP™ Platform, explore new AI-driven market opportunities, and continue improving shareholder value under its new leadership and Board of Directors.

How does the NFT algorithm benefit clinical procedures?

The Near-Field Tracking (NFT) algorithm provides tissue-specific feedback and color-coded characterization in real-time, which improves procedural efficiency and accuracy, thereby reducing ablation time and enhancing patient outcomes.

Is BioSig publicly traded?

Yes, BioSig Technologies, Inc. is publicly traded on the Nasdaq Capital Market under the ticker symbol BSGM.

What steps has BioSig taken to comply with Nasdaq requirements?

BioSig has addressed compliance issues with the Nasdaq Hearings Panel and implemented a reverse stock split to meet the minimum bid price requirement.

Where can I find more information about BioSig?

More information about BioSig Technologies, Inc. can be found on the SEC's website at http://www.sec.gov, as well as on their official investor relations page.

Stock BSGM logo
BioSig Technologies, Inc.

Nasdaq:BSGM

BSGM Rankings

#5249 Ranked by Market Cap
N/A Ranked by Dividends

BSGM Stock Data

22.92M
13.37M
30.77%
1.13%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
WESTPORT